We are thrilled to share that Ms. Jennifer Che, our President and Managing Director, has been recognized in IAM Strategy 300 Global Leaders 2026. This follows our recent announcement recognizing Ms. Che in the list of IAM Global Leaders 2026, which focuses on patent prosecution.

IAM Strategy 300 showcases the top strategy experts in the IP world. It is the “only resource of its kind, acknowledging leaders from across in-house, private practice and service provider roles”. A slot in the 300 is the “mark of a professional whose approach to intellectual property is regarded by peers as truly strategic in nature.”

IAM's comprehensive research process involved gathering nominations and insights from thousands of sources over a five month period, leading to in-depth interviews with selected candidates.

Jennifer's inclusion in this elite group is a testament to her ability to inspire and innovate, continually providing exceptional value to our clients and setting a benchmark in the industry.


Please join us in congratulating Jennifer on this well-deserved recognition. Her expertise and dedication to her work make her an invaluable asset to our team and our clients.

Our Past Events

Recommended Insights

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

21 September 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

10 March 2025
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

12 November 2018
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]
Top crossarrow-right